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The aim of this study is to investigate whether 111Indium-labelled recombinant FVIIa (rFVIIa) could be a potential
radiopharmaceutical for localization of bleeding sources. DTPA-conjugated rFVIIa was radiolabelled with 111In chloride. In vitro
binding eﬃciency of 111In-DTPA-rFVIIa to F1A2-Mab-sepharose was 99% in buﬀer, while it was 88–82% in serum. The binding
eﬃciency of 111In-DTPA-rFVIIa to TF (1–209)-sepharose was 48% in buﬀer whereas 39%–36% in serum, respectively. In vivo
experiment was conducted in healthy rats, and gamma camera images were taken immediately after iv. administration of 1.6–1.8
MBq 111In-DTPA-rFVIIa up to 120–130 min. Five min after administration of 111In-DTPA-rFVIIa, percentage of 111In activity was
6.0%inthecardiacregionand24.5%intheliverregion.After2hoursactivitywasdecreasedto3.3%inheartwhileithadincreased
to 42.0% in the liver. The 111In-DTPA-rFVIIa might be a potential radiopharmaceutical for visualisation of tissues with signiﬁcant
TF expression such as acute bleeding lesions in the gastrointestinal tract.
1.Introduction
Theaimofourinvestigationwastodevelopanewradiotracer
usingcommerciallyavailablerecombinantactivatedcoagula-
tion factor VII (rFVIIa, NovoSeven) for localisation of acute
bleeding and cancer. rFVIIa is structurally and functionally
similar to human plasma-derived coagulation factor VIIa, a
glycoprotein of 406 amino acid residues with a molecular
weightof50kDa[1].Ithasbeenusedintreatmentofpatients
with various bleeding disorders like hemophilia A and B
patients with inhibitory antibodies and patients with factor
VII deﬁciency and Glanzmann thrombasthenia [2–7].
Blood clotting is initiated via tissue factor (TF), which
is normally not exposed to the blood but is constitutively
ex-pressed on cells separated from the circulation. Vascular
inju-ry exposes TF-rich extravascular tissue, and FVIIa
interactswithTFformingtheFVIIa/TFcomplexandinitiates
the coagulation cascade. Through thrombin generation this
leads to formation of a ﬁbrin clot. In addition to its general
haemostatic function, TF has also been reported to come in
contact with FVIIa in the circulation as a result of structural
defectsin thevesselwall,angiogenic stimulation, entryto the
bloodstream of large numbers of TF-expressing cells, which
includes inﬂammatory leukocytes, leukaemic blast, and
cancer cells [8–10]. Interaction between the FVIIa and
TF indu-ces the proliferation of certain cancer cells [11, 12].
Therapeutic agent conjugated to FVIIa or FVII resulted in
speciﬁctargeteddrugdeliveryoftherapeuticagenttotheTF-2 International Journal of Molecular Imaging
expressing tumor cells [13–16]. Several studies have shown
over expression and involvement of TF in rapidly growing
malignant tumors [17].
TF has previously been targeted for imaging with
antibody-coated perﬂuorocarbon emulsion nanoparticles
against extracellular domain of TF (1–208) to identify the
angioplasty-induced expression of tissue factor by smooth
musclecellswithinthetunicamediainpigs[18].Inaddition,
ﬂuorescence-conjugated antibodies against TF were used in
real-time in vivo imaging of tissue factor during arterial
thrombus formation in the mouse [19]. We suggest that
rFVIIa could be a protein of potential interest for in vivo
imaging by targeting to TF.
The localization of the rather frequently occurring acute
gastrointestinal bleeding is often a serious clinical problem.
Endoscopy and radiographic examinations including arte-
riography are the most commonly used imaging modalities
for localization of bleeds, and treatment combined with
endosonography is often successful [20, 21]. However, the
lesion is not always localized by this, and explorative lapa-
rotomy comes into consideration as the ﬁnal option. Even
thisveryinvasiveapproach,whichisassociatedwithasigniﬁ-
cant rate of complications, may occasionally also fail to
identify the bleeding lesion, and other techniques including
gamma camera imaging with 99mTc-labelled red blood cells
have been applied.
The latter technique is based on the principle of showing
the extravasation site of the blood from the circulation,
and bleeding scintigraphy has been quite useful [22]. The
requirement for an excessive bleeding, that is, more than
1mL/min[23, 24] at the time of tracer injection and subse-
quent image acquisition constitute is a serious limitation of
the technique. Therefore, there is a need for a more sensitive,
noninvasivediagnostictoolforlocalizationofacutebleeding.
WehavepreviouslyhypothesizedthatrFVIIacouldbepoten-
tial tool to develop a radiotracer such as radiolabelled
rFVIIa for localization of bleeding lesions [25]i no r d e r
to visualize the bleeding site in a more direct manner,
since rFVIIa binds directly to the tissue-exposing TF at
the exact site of the bleeding lesion. Tc-99m would be the
optimal radioisotope for radiolabelled rFVIIa, but earlier
studies with such a tracer were unsuccessful [25]. 111In-
labelled rFVIIa might be an alternative candidate for such a
radiopharmaceutical.
The most common method attaching 111In to a protein
is via a chelation reaction of a bifunctional chelating agent,
whichwaspreviouslyconjugatedto aproteinor polypeptide.
Diethylene-triaminepenta-aceticacid(DTPA)anditsderiva-
tives are the most popular chelating agents employed for
111In as well as some other metallic nuclides [26–28]. DTPA
is often used as a bifunctional chelating agent conjugated
to proteins like tumor-targeting probes such as monoclonal
antibodies [29, 30] and Fab fragments [31, 32].The radiola-
beling of proteins with trivalent metallic isotopes and ability
of DTPA to react with proteins to establish a stable amide
bonds in a single-step process are well documented [26, 33–
35],and 111Indiumlabelingcanbeperformedwithoutlossof
labelling eﬃciency after long-term storage DTPA-conjugated
protein [36].
2.MaterialsandMethods
2.1. Materials. We used 111In chloride from Tyco Health-
care/Mallinckrodt Medical, cyclic diethylene triamine pen-
taacetic acid (cDTPA), dimethyl sulfoxide (DMSO) anhy-
drous, trisodium citrate dehydrate, glycyl-glycine, Costar
Spin-X centrifuge tube from Sigma-Aldrich, and ITLC-SG
from Pall Corporation, USA. rFVIIa, TF (1–209) and mono-
clonal mouse anti-FVII antibody, and F1A2 were from Novo
Nordisk A/S, Bagsværd, Denmark. Slide-A-Lyzer Dialysis
Cassettes were from Thermo Fisher Scientiﬁc, IL, USA.
CNBr-activated sepharose-4B and PD-10 columns were ob-
tained from Pharmacia, Uppsala, Sweden. All other reagents
used in the experiments were analytical-grade products from
Sigma-Aldrich if not mentioned from other suppliers.
2.2. Preparation of DTPA-rFVIIa. rFVIIa in glycyl-glycine
buﬀer, pH 7.5 (10mM glycyl-glycine, 150mM NaCl, 10mM
CaCl2) was dialysed overnight against 2 times 2.5 litres of
borate buﬀer saline pH 8.2 containing 10mM CaCl2.c D T P A
(1:1 ratio of DTPA to rFVIIa) dissolved in DMSO anhydrate
was added to the 1.35mg/mL rFVIIa and incubated at +4◦C
for 4 hours. After the incubation, free DTPA was removed
by overnight dialysis against 2 times 2 litres of glycyl-glycine
buﬀer, pH 7.4. The DTPA-rFVIIa was aliquoted and stored at
−80◦C for radiolabeling with 111In-chloride.
2.3. Radiolabeling. The radiolabeling was carried out by
addition of double volume of 500mmol/l sodium citrate
buﬀer, pH 6 to 10Mbq of 111In chloride (2:1v/v; buﬀer:
111In chloride). After 5min 20μL of DTPA-rFVIIa conjugate
prethawed at RT was added, and the reaction was mixed
and then incubated at RT for 30min. For the rat exper-
iments, 100μL of DTPA-rFVIIa labelled with 37MBq of
111In chloride was used. Finally 111In-labelled DTPA-rFVIIa
was puriﬁed using glycyl-glycine buﬀer-equilibrated PD-10
column and eluted with glycyl-glycine buﬀer.
2.4. Labelling Eﬃciency. Labelling eﬃciency was determined
on ITLC-silica-impregnated glass ﬁber sheets (ITLC-SG)
fromtheﬁnalproduct,and5μLwasappliedtotheITLCstrip
that was developed with 50mmol/l sodium citrate buﬀer
for 5–10min. Radioactivity was measured by an instant
chromatography scanner (VCS-101, Veenstra Instruments)
equipped with a NaI crystal.
2.5. Immobilization of TF (1–209) and F1A2-Mab. The solu-
bleTF(1–209)andCa2+-dependentmonoclonalmouseanti-
FVII antibody, F1A2-MAB, were immobilised on to CNBr-
activated sepharose-4B with TF (1–209) or with F1A2-MAB
as described by the manufacturer at a ﬁnal density of 9mg
TF (1–209) per mL sepharose-4B and 10mg F1A2-MAB
per mL sepharose-4B. Finally TF-(1–209) and F1A2-MAB-
immobilised sepharose-4B was blocked with 1M glycine,
0.1M NaHCO3, 0.5M NaCl, pH 8.5.
2.6. 111In-Labelling, Serum Stability and Binding Eﬃciency
Studies. Stability studies on 111In-labelled DTPA-rFVIIaInternational Journal of Molecular Imaging 3
were performed by addition of 100μL of 100mM EDTA
and incubated for 5min after radiolabelling in citrate buﬀer
for 30min. Then labelling eﬃciency was determined as
mentioned earlier. Stability studies were performed in assay
buﬀer (10mM glycyl-glycine, 150mM NaCl, 10mM CaCl2,
0.1% BSA, pH 7.5) and in human serum with 111In-DTPA-
rFVIIafromthreediﬀerentradiolabeling.A5–10μLof2.5μg
111In-DTPA-rFVIIa elute from PD-10 column was added
to 270μL human serum and incubated for 1 hour with
constant shaking at room temperature. After the incubation
100μLTF(1–209)-sepharoseorF1A2-MAB-sepharose(50%
suspension) was added, and the binding was allowed for 1
hour at room temperature with constant shaking. Stability
studies in assay buﬀer and serum for 0 hour were performed
similarly to 1-hour serum incubation studies without prior
incubation for1 hour in assay buﬀeror serum. Total reaction
contentwascentrifugedinCostarSpin-Xcentrifugecellulose
a c e t a t em e m b r a n eﬁ l t e rt u b e sw i t hp o r es i z eo f0 . 4 5 μm
at 6000rpm for 10min using Heraues Biofuge 15, Bie &
Berntsen, Denmark. The radioactivity of sepharose beads
and ﬁltrate was measured using Cobra II auto-gamma,
Packard.
The binding eﬃciency of 111In-DTPA-rFVIIa to TF (1–
209)-sepharose and F1A1-MAB-sepharose was calculated
using the following formula:
Binding eﬃciency (%)
=
Sepharose beads

cpm

− Filterate

cpm

Sepharose beads

cpm

+ Filterate

cpm

−2 ∗Background

cpm
 ∗100%.
(1)
2.7.InVivoStudiesinRats. Animalcareandallexperimental
procedureswereperformedundertheapprovaloftheDanish
Animal Welfare Council (2006/561-1124). An iv. cannula
was introduced into a tail vein in 6 healthy, male Sprague-
Dawley rats, mean bwt 303g (range 284–323), three rats at
a time with 30-min interval. They were anaesthetized with a
mixture of Hypnorm (fentanyl citrate 0.315mg/mL and ﬂu-
anisone 10mg/mL) and Dormicum (midazolam 5mg/mL),
0.3mL/100g body weight, and maintained anaesthetized
with 0.15mL/100g body weight every 20min. 1.6–1.8MBq
111In-DTPA-rFVIIawasinjectedintothecannulaandﬂushed
with 0.3mL saline solution. Immediately following the
injection the group of three rats at a time were positioned on
aMediso1-headedgammacamera(MedisoMedicalImaging
Systems, Budapest, Hungary) with a medium energy, general
purposecollimator.Sixdynamic5-minimageswereacquired
immediately after radioisotope injection, followed by static
images after 1 and 2 hours. After the end of the two hours
image acquisition of the last three rats 70MBq of 99mTc-
labelled human serum albumin (Vasculosis) was injected
into the tail vein of rats 4–6 to verify the regions of interest
(ROI) deﬁnitions of the heart and the liver.
Dynamic and static images were obtained in a matrix
size of 256 × 256. ROIs were drawn around the heart, the
liver, and the total body, which were rather easy to deﬁne in
all rats from the indium images and in agreement with the
99mTc-labelled albumin images created for deﬁnitions of the
ROIs. Indium count rates were not cor-rected for physical
decay or background. After the last image acquisition rats
were sacriﬁced, and a sample of around 1mL blood was
successfully obtained from the neck vessels, and count
rates (cps/mL anticoagulated blood) were determined in a
COBRA well counter. Assuming a mean total blood volume
in each rat of 20mL (corresponding to a human blood
volumeof5litres/70kgbwt),thefractionoftheinjecteddose
of 111In activity still circulating in the vascular system was
calculated by comparison with the count rate of an 111In
standard determined in the COBRA well counter.
3. Results
3.1. 111In Labelling, Stability, and Binding Eﬃciencies. The
radiolabeling yield of the puriﬁed product of 111In-DTPA-
rFVIIa varied between 88–97%, and speciﬁc activities of 9–
13MBq/μmol were used for in vitro studies. No signiﬁcant
loss of 111Indium bound to DTPA-rFVIIa was observed
even after addition of the strong chelator like EDTA. The
median binding eﬃciency of 111In-DTPA-rFVIIa to F1A2-
Mab-sepharosewas99%(84–99%)inassaybuﬀer,anditwas
88% (87-88%) just after the labelling and fell to 82% (range
79–85%)after1-hourincubationintheserumstabilitystudy.
The binding eﬃciency of 111In-DTPA-rFVIIa to TF (1–209)-
sepharosewas39%(range28–44%)for0houranddecreased
to 36% (range 33–48%) after 1 hour in serum compared to
48% (range 41–53%) after 1-hour incubation in assay buﬀer
(Figure 1).
3.2. In Vivo. After injection of rFVIIa into the rats, heart
and big blood vessels were immediately visualized. The
splanchnic organs were also clearly identiﬁed in the early
images and slowly increased their activity uptake. An ROI
around the heart in the six rats during the ﬁrst 5 minutes
showed a median value of 6.0% 111In activity, calculated
as the count rate in the cardiac region as percentage of
the total rat count rate. It was 24.5% in the splanchnic
(liver) region in percentage of total rat count rate; over the
following two hours it gradually decreased to a median 3.3%
(range 2.7–4.5%), that is, to about half the initial value and
increased to 42.0% in the splanchnic region (Figures 2 and
3). Assuming that the heart contains around 5% of the total
rat blood volume (in man around 250/5000mL), it can
be estimated that after 5 minutes the In-rFVIIa circulating
activity is ca. 20 × 5%; that is, all In-rFVIIa activity is within
the circulation. After 10 minutes it had decreased to ca.
80% of total In-rFVIIa activity. After 2 hours this value was
reduced to about 50%. The blood samples showed similar
orders of magnitude. The average value contained 48kBq4 International Journal of Molecular Imaging
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Figure 1: In vitro binding eﬃciency of 111In-FVIIa to TF (1–209)-
sepharoseandF1A2-MAB-sepharose:Medianvaluesof3individual
experiments on binding eﬃciency of 111In-FVIIa to TF (1–209)-
sepharose (empty bars) and F1A2-MAB-sepharose (solid bars)
in assay buﬀer and human serum at 0-hour and after 1-hour
incubation.
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Figure 2: In vivo 111In-FVIIa activity in liver and heart versus
total radioactivity: changes over time of 111In radioactivity (median
values)in6ratsintworegionsofinterestcorrespondingtotheheart
(grey circles) and liver (black circles) against total.
(40–55kBq), that is, around 40% of the injected activity of
1.5MBq.
4. Discussion
Current methods for the detection of lesions causing acute
gastrointestinalbleedinghavesigniﬁcantlimitationsofsensi-
tivity, including scintigraphy with 99mTc-labelled autologous
red blood cells, which often requires a rather high rate
of active bleeding; imaging of radiolabelled rFVIIa could
provide a potentially more sensitive, noninvasive diagnostic
tool. Factor VII is a very important component in the
coagulation cascade. It is present in the circulating blood
and binds to TF when exposed at the site of injury. The
radioisotope of choice for gamma camera imaging would
of course be 99mTc, but unfortunately in our recent study
we failed to create a 99mTc-labelled rFVIIa ligand stable
in vivo [25], 111In could be an alternative radioisotope as
demonstrated, for example, with the very successful tracer
forsomatostatinreceptorimaging, 111In-labelledPentreotide
[37]. This preliminary study has shown that rFVIIa can
be eﬀectively labeled with 111In with preserved biological
properties.
It is always a challenge to develop a radiopharmaceutical
without loss of intact biological activity. A minor loss of
intactbiologicalactivityduringtheradiolabelingmayalmost
always be anticipated because of the inﬂuence of even
subtle changes related to the radiolabeling procedure on
the molecular structure, which determines the biomolecular
property. In order not to aﬀect the biological activity of
rFVIIa and to avoid the protein cross-linking associated
with high DTPA to ligand ratio [35], we reduced the
DTPA:rFVIIa ratio to a value as low as possible (1:1). The
DTPA conjugation was performed in borate saline buﬀer
with pH 8.2 containing 10mMCaCl2, which is a good
buﬀer for the conjugation; however, high pH may aﬀect
the stability of rFVIIa. 111Indium labelling of DTPA-rFVIIa
was performed in citrate buﬀer, which among diﬀerent
buﬀers tested gave the highest labelling eﬃciency. But the
citrate buﬀer may be less optimal because of its chelating
properties of calcium ions, the presence of which is essential
for the preservation of biological activity of rFVIIa. The
conjugation and labelling conditions were sub-optimal, but
with compromises we obtained a labelling yield of rFVIIa
which was in an acceptable range. Unstable and nonspeciﬁc
binding of indium to DTPA-protein conjugate may lead
to increased liver uptake and higher background activity,
previously reported [38]. To avoid this problem and to
demonstrate stability of 111In-DTPA-rFVIIa complex, we
introduced EDTA to the labelling procedure prior to serum
stability studies. Analysis of conjugation eﬃciency and
protein cross-linking needs to be considered in futurestudies
with conjugation of rFVIIa with cDTPA, which might reveal
loss of in vitro binding eﬃciency to sTF (1–209).
The binding eﬃciency of 111In-DTPA-rFVIIa to TF (1–
209) was reduced compared to F1A1-MAB. This may suggest
that rFVIIa sites involved in the binding to TF are more
sensitive to the labelling procedure than the epitope for the
F1A2 antibody. The observed loss of biological activity may
be due to an elevated pH during the conjugation, lack of
calcium ions during the radiolabeling, the conjugation of
DTPA at the binding site of TF (1–209), interchain cross-
linking of rFVIIa by DTPA, and ﬁnally by oxidation of
methionineresiduesofrFVIIa[35,39,40],whichmayleadto
reduction of the binding eﬃciency of 111In-DTPA-rFVIIa to
TF (1–209). Modiﬁcation of the conditions for conjugation
and for the radiolabeling procedure could improve the
binding eﬃciency of 111In-DTPA-rFVIIa especially to TF (1–
209) in vitro. Our results suggest that the N-terminal gamma
glutamic acid domain, which is a calcium binding domain
of rFVIIa unaﬀected by the DTPA conjugation and by 111In-
labelling whereas it interfered to some degree with the TFInternational Journal of Molecular Imaging 5
(a) (b)
Figure 3: 111In-FVIIa scintigraphy in three rats with early and delayed images: scintigraphy of three rats at 1–10min (a) and 2 hours (b)
after iv. injection of 1.6–1.8MBq 111In-FVIIa. The pointed arrows show the splanchnic organs; ﬁlled arrows point to the cardiac region.
binding domain. The binding of rFVIIa to TF is a crucial step
to form the FVIIa/TF complex and to initiate the coagulation
cascade through generation of thrombin and formation of
a stable ﬁbrin clot. In vitro serum stability studies of 111In-
DTPA-rFVIIa were performed in human serum to examine
the risk of human serum-induced enzymatic stability. 111In-
DTPA-rFVIIawasstableinserumfor1hourwithanegligible
loss of its binding eﬃciency to TF (1–209) and F1A2-MAB
compared to the binding eﬃciency in assay buﬀer.
In vivo studies performed in rats suggest that all 111In-
DTPA-rFVIIa activity was circulating after 5 minutes. After
10 minutes the 111In-activity had decreased to around 80%
and after 2 hours to around 50% according to the calculation
of 111In-activity in the cardiac ROI of the gamma camera
images, that is, a ROI almost only representing blood volume
activity (99mTc-labelled human serum albumin images were
used for conﬁrmation of ROI). The fairly consistent two-
hour values calculated from the gamma camera images were
in nice agreement with the calculation from the blood sam-
ples drawn after two hours. The data thus strongly suggest
that 40–50% of the injected 111In activity is circulating
after two hours, thus allowing for a longer time span for
possible imaging than the current radionuclide technique
using 99mTc-labelled red cells.
The circulating half-life of 111In-DTPA-rFVIIa was mea-
sured both by using calculations of in vivo imaging data and
by counting blood samples as an in vitro measurement. In
vivo images from the six rats give complete biodistribution,
and they were very consistent therefore we ﬁnd it is not
necessary to do radioactivity measurement in each major
organ. It must be added that we only measured 111In acitivity
in the images and blood samples. Theoretically those count
rate data could represent other 111In compounds or free
111indium, but the latter seems unlikely, since free 111indium
is rapidly excreted via the kidneys, which never got visible
in our images. Other In-labeled compounds from rFVIIa
metabolism cannot be excluded, but appear less likely, since
rFVIIa is primarily excreted via the liver and does not remain
in the circulation.
The in vivo imaging analysis was performed for 2 hours
due to the half-life of circulating rFVIIa reported to be
around 2-3 hours with some variations in pharmacokinetic
studies in rodents. Since the half-life for 125I-rFVIIa, con-
sidered to closely reﬂect biological rFVIIa activity, in rats is
80–90min [41], we restricted our imaging time for a similar
duration. An optimal time window for in vivo imaging
of acute bleeding would ideally allow for imaging up to
several hours after tracer injection, because acute gastro-
intestinal bleeding often occurs as repeated bleeding periods
for a few hours interrupted by hours of no bleeding. Such
a time window demands a tracer with a longer half-life in
the circulation. In this study, investigation of 111In-DTPA-
rFVIIa, performed in healthy rats only, serves as a model
and a ﬁrst step to show whether it is potentially useful to
apply 111In-DTPA-rFVIIa for imaging acute bleeding lesions
and possible other disease. This has to be shown in future
investigations.
Since signiﬁcant TF expression has also been found in
several cancers [42] and apparently related to formation of
distant metastases [43–46], a radiolabelled gamma emitter
or preferably a positron emitter-labeled rFVIIa could be
interesting for the diagnosis of or monitoring of progres-
sion in some malignant diseases. The time interval for
cancer imaging may need to be longer, allowing for the
binding of the ligand to less well-perfused tumour cells
and clearing of surrounding tissue. Thus 111In-labelled
rFVIIa or possibly rather TF with active site-inhibited
FVIIa (ASIS) could be suitable also for cancer imaging
[13]. PET isotopes like 68Ga (half-life: 68min) or 64Cu
(half-life: 12.7h), labelled to DOTA-conjugated rFVIIa,
may be a potentially better isotope for cancer imaging
with the advantage of PET/CT with signiﬁcantly better
spatial image resolution, a higher sensitivity, and being
quantitative.6 International Journal of Molecular Imaging
Limitations of the Study. The in vivo study included six rats
only, which is a very limited number of experimental ani-
mals, and the animals only comprised healthy rats without
acute bleeding. However, the values were very consistent in
the six rats, and in a previous study in bleeding rabbits it has
been shown that 123I-rFVIIa can detect acute gastrointestinal
bleeding [47], but unfortunately 123I is not useful for acute
imaging purposes because of its shorter half-life.
5. Conclusion
Recombinant FVIIa can be labelled successfully with
111Indium chloride; 111In-DTPA-rFVIIa is quite stable in
vitro, also incubated in serum, with a minor loss of binding
eﬃciency to TF (1–209) and F1A2-MAB compared to bind-
ing eﬃciency in assay buﬀer. Half of the 111In-labelled rFVIIa
was still in circulation two hours after iv. injection. Thus it
may be a potential radiopharmaceutical for visualisation of
tissues with signiﬁcant TF expression such as acute bleeding
lesions in the gastrointestinal human tract and possibly also
for cancer imaging.
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